drugset

drugset / Trial / NCT01557777

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

NCT01557777 ↗

Phase 2 Completed 17 enrolled AbbVie

Non-randomizedSingle-groupOpen-labelBasic science

Summary

Open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).

Timeline

Start: 2012-06
Primary completion: 2013-07
Completion: 2013-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Navitoclax	Small molecule	—	—

Indications